Company · MRK
Merck & Co.
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
145
47 still marketed
Novel approvals
59
Approvals since 2021
117
Originals and new uses
Phase 3 trials
746
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Keytruda Qlex new use Oct 16, 2026
- Keytruda new use OrphanOct 16, 2026
- Enflonsia new use Oct 14, 2026
- Welireg new use Sep 24, 2026
- Winrevair new use OrphanSep 21, 2026
- Lipfendra approved NovelPriority reviewJul 15, 2026
- Keytruda Qlex new use Priority reviewJul 10, 2026
- Keytruda new use Priority reviewJul 10, 2026
- Keytruda Qlex new use Jun 24, 2026
- Keytruda new use Jun 24, 2026
Drugs in development (47)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- MK-1084CalderasibPhase 38 trials
Merck & Co. · Non-small Cell Lung Cancer, Colon Adenocarcinoma, Rectal Adenocarcinoma
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- NemtabrutinibMK-1026, ARQ 531Phase 36 trials
Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- AlimatravirMK-8527Phase 34 trials
Merck & Co. · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, HIV
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
- coformulation favezelimabMK-4280APhase 33 trials
Merck & Co. · Small Cell Lung Carcinoma, Solid Tumors, Hematologic Malignancies
- H1 receptor antagonistPhase 33 trials
Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer
- ISLPhase 33 trials
Merck & Co. · HIV-1 Infection
- ULOMK-8507, UlonivirinePhase 33 trials
Merck & Co. · Human Immunodeficiency Virus Type 1 (HIV-1) Infection, HIV-1 Infection
- VinflunineJavlorPhase 33 trials
Merck & Co. · Bladder Cancer, Urothelial Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
Recruiting Phase 3 trials
Largest first.
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07071623 · 4,580 participants (planned) · Start Nov 10, 2025 · Primary completion Oct 18, 2027
Drug: MK-8527; Emtricitabine/tenofovir disoproxil (FTC/TDF) and 2 more · For: Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
Sites: Homabay County, Kenya; Thika, Kenya; Nairobi, Kenya · 30 sites in all
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03486873 · 3,500 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 4, 2043
Drug: Pembrolizumab; Standard of Care (SOC) and 5 more · For: Solid Tumors; Hematologic Malignancies
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 782 sites in all
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06667700 · 3,082 participants (planned) · Start Dec 2, 2024 · Primary completion Jan 26, 2031
Drug: Molnupiravir; Placebo · For: Coronavirus Disease (COVID-19)
Sites: Cullman, Alabama; Paradise Valley, Arizona; Phoenix, Arizona · 230 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07874815 · 2,136 participants (planned) · Start Nov 2, 2026 · Primary completion Apr 29, 2029
Drug: Ensifentrine; Standard of Care (SOC) · For: Pulmonary Disease, Chronic Obstructive
Sites: Hialeah Gardens, Florida; Loxahatchee Groves, Florida; Valparaiso, Indiana · 7 sites in all
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06393374 · 1,530 participants (planned) · Start Jun 24, 2024 · Primary completion Dec 16, 2030
Drug: Pembrolizumab; Sacituzumab tirumotecan and 1 more · For: Triple-Negative Breast Cancer
Sites: Mobile, Alabama; Chandler, Arizona; Fountain Valley, California · 317 sites in all
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06925737 · 1,440 participants (planned) · Start May 13, 2025 · Primary completion Jun 26, 2028
Drug: Ifinatamab deruxtecan; Docetaxel and 2 more · For: Prostate Cancer; Prostatic Neoplasms
Sites: Phoenix, Arizona; Clovis, California; Duarte, California · 303 sites in all
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06651281 · 1,380 participants (planned) · Start Nov 25, 2024 · Primary completion Dec 17, 2037
Drug: Tulisokibart; Placebo to tulisokibart · For: Crohn Disease; Colitis, Ulcerative
Sites: Bristol, Connecticut; Ypsilanti, Michigan; Liberty, Missouri · 37 sites in all
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136650 · 1,314 participants (planned) · Start Dec 18, 2023 · Primary completion May 10, 2028
Drug: Opevesostat; Dexamethasone and 5 more · For: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
Sites: Tucson, Arizona; Irvine, California; Los Angeles, California · 330 sites in all
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136624 · 1,310 participants (planned) · Start Dec 31, 2023 · Primary completion Nov 30, 2028
Drug: Opevesostat; Abiraterone acetate and 5 more · For: Prostate Cancer Metastatic
Sites: Orange, California; Palo Alto, California; Riverside, California · 288 sites in all
Marketed drugs (47)
Newest FDA action first.
- Welireg Belzutifan · 2021
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · 2025
- Keytruda Pembrolizumab · 2014
- Enflonsia Clesrovimab-Cfor · 2025
- Delstrigo Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate · 2018
- Pifeltro Doravirine · 2018
- Winrevair Sotatercept-Csrk · 2024
- Janumet Xr Metformin Hydrochloride, Sitagliptin Phosphate · 2012
- Segluromet Ertugliflozin, Metformin Hydrochloride · 2017
- Janumet Metformin Hydrochloride, Sitagliptin Phosphate · 2007
- Lipfendra Enlicitide Decanoate · 2026
- Steglujan Ertugliflozin, Sitagliptin Phosphate · 2017
- Steglatro Ertugliflozin · 2017
- Idvynso Doravirine, Islatravir · 2026
- Follistim Aq Follitropin Alfa/Beta · 2004
- Noxafil Posaconazole · 2006
- Noxafil Powdermix Kit Posaconazole · 2021
- Verquvo Vericiguat · 2021
- Belsomra Suvorexant · 2014
- Prevymis Letermovir · 2017
- Prevymis Letermovir · 2024
- Prevymis Letermovir · 2017
- Bridion Sugammadex Sodium · 2015
- Ganirelix Acetate Ganirelix Acetate · 1999
- Ohtuvayre Ensifentrine · 2024
- Nuvaring Ethinyl Estradiol, Etonogestrel · 2001
- Januvia Sitagliptin Phosphate · 2006
- Temodar Temozolomide · 2009
- Zinplava Bezlotoxumab · 2016
- Pregnyl Gonadotropin, Chorionic · 1976
- Invanz Ertapenem Sodium · 2001
- Stromectol Ivermectin · 1996
- Intron A Interferon Alfa-2b · 1986
- Remeron Soltab Mirtazapine · 2001
- Isentress Raltegravir Potassium · 2011
- Isentress Raltegravir Potassium · 2013
- Isentress Hd Raltegravir Potassium · 2007
- Emend Aprepitant · 2003
- Clarinex Desloratadine · 2004
- Pegintron Peginterferon Alfa-2b · 2001
- Zolinza Vorinostat · 2006
- Noxafil Posaconazole · 2006
- Clarinex Desloratadine · 2002
- Clarinex Desloratadine · 2002
- Lotrimin Af Clotrimazole · 1989
- Lotrimin Af Clotrimazole · 1989
- Lotrimin Af Clotrimazole · 1989
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.